Compare PRGS & ENOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRGS | ENOV |
|---|---|---|
| Founded | 1981 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Fluid Controls |
| Sector | Technology | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.7B |
| IPO Year | 1991 | 2008 |
| Metric | PRGS | ENOV |
|---|---|---|
| Price | $43.55 | $27.02 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | ★ $68.00 | $51.17 |
| AVG Volume (30 Days) | 501.9K | ★ 815.6K |
| Earning Date | 01-20-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.09 | N/A |
| Revenue | $940,126,000.00 | ★ $2,233,266,000.00 |
| Revenue This Year | $32.42 | $9.27 |
| Revenue Next Year | $1.44 | $4.56 |
| P/E Ratio | $39.83 | ★ N/A |
| Revenue Growth | ★ 31.41 | 11.57 |
| 52 Week Low | $39.00 | $25.47 |
| 52 Week High | $69.88 | $49.38 |
| Indicator | PRGS | ENOV |
|---|---|---|
| Relative Strength Index (RSI) | 57.26 | 36.08 |
| Support Level | $39.14 | $26.69 |
| Resistance Level | $41.76 | $30.93 |
| Average True Range (ATR) | 1.14 | 1.33 |
| MACD | 0.45 | -0.12 |
| Stochastic Oscillator | 91.31 | 7.31 |
Progress Software Corporation provides software operate in one operating segment: software products for the development, deployment, and management of responsible, AI-powered applications and digital experiences. Following are products: Chef, Corticon, Data Direct, Developer Tools, Flowmon, Kemp LoadMaster, MarkLogic, MOVEit, OpenEdge, Semaphore, ShareFile, Sitefinity, WhatsUp Gold. Geographical regions include United States, Canada, EMEA, Latin America, and Asia Pacific.
Enovis Corp is a medical technology company that offers medical devices and services across the continuum of patient care, from injury prevention to joint replacement to rehabilitation after surgery, injury, or degenerative disease. Its reportable segments are Prevention & Recovery (P&R) and Reconstructive (Recon). The company generates the maximum revenue from the Prevention & Recovery segment, which includes products that are used to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports-related injuries. The Reconstructive segment provides a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and surgical productivity tools. Geographically, it derives key revenue from the U.S.